Pfizer to initiate new Phase III cancer studies

Of these seven Phase III studies two are open and enrolling, and five are planned to begin by the end of 2008. These trials involve three different compounds: Sutent, axitinib and CP-751,871, and will focus on four types of cancers – hepatocelluar, non-small cell lung cancer, renal cell carcinoma and prostate cancer.

Pfizer also said that it has 22 oncology compounds in a total of 232 ongoing or planned, sponsored, oncology clinical studies.

Charles Baum, vice president of global research and development at Pfizer, said: “We are seeing our sustained efforts in oncology mature as our development programs continue to advance into late-stage clinical trials.”